Helen Bristow

1 week ago | thepathologist.com | Helen Bristow

With machine learning’s ability to recognize cancerous tissue on digital histology images well established, researchers are beginning to apply that power to other diseases. A team of researchers at the University of Cambridge has been investigating whether a machine learning tool might be able to improve the efficiency of celiac disease diagnosis – a process that is notoriously slow.

1 week ago | theanalyticalscientist.com | Helen Bristow

The prognostic power of spatial proteomics has given rise to a new tool for predicting the recurrence of hepatocellular carcinoma (HCC) after resection surgery. The system, described in , uses AI to interrogate the distribution of natural killer (NK) cells in the tumor microenvironment and identify high-risk patients. Here, corresponding author Joe Yeong shares details of the study, the prognostic scoring system that was developed, and its potential impact for patients with liver cancer.

2 weeks ago | thepathologist.com | Helen Bristow

Spatial biology is offering fresh insights into cancers, neurodegenerative diseases, and autoimmune disorders, and helping researchers identify new biomarkers to improve diagnosis and treatment. But what is spatial image data science – and how does it fit into the picture? Here, Gourab Chatterjee, Director, Product Strategy and Management, and Lorenz Rognoni, Senior Director, Image Data Science, at Vizgen, guide us through the fundamentals.

2 weeks ago | thepathologist.com | Helen Bristow

Endometriosis affects 10 percent (190 million) of reproductive age women and girls globally. Symptoms include severe, life-impacting pain, depression, and infertility. It is a seriously debilitating disease, which can be associated with increased risk of ovarian cancer, and it is diagnostically challenging – often taking years to confirm. UK company, PrecisionLife, has been looking for a better way to diagnose and treat women with endometriosis.

3 weeks ago | thepathologist.com | Helen Bristow

On March 31, 2025, Judge Sean D Jordan of the US District Court for the Eastern District of Texas vacated the FDA rule that would have regulated laboratory developed tests (LDTs) as medical devices under the Federal Food, Drug and Cosmetic Act. The rule – issued by the FDA on May 6, 2024, following years of consultations – angered many in the pathology community.